Literature DB >> 24305629

A direct method for the measurement of everolimus and sirolimus in whole blood by LC-MS/MS using an isotopic everolimus internal standard.

Phillip E Morgan1, Nigel W Brown, J Michael Tredger.   

Abstract

BACKGROUND: Whole-blood concentrations of the immunosuppressant drugs everolimus and sirolimus should be monitored. A sensitive and selective method offering the detection of both analytes in small sample volumes would optimize the throughput of samples for sirolimus or everolimus analysis. This study reports the validation of a liquid chromatography tandem mass spectrometry method, including a stable isotope internal standard, for the simultaneous measurement of everolimus and sirolimus.
METHODS: Whole-blood samples (20 μL) were treated with ammonium bicarbonate (20 μL), zinc sulfate (20 μL), and internal standard solution ((13)C(2)D(4)-everolimus in acetonitrile, 100 μL). After centrifugation, 20 μL of the supernatant was injected onto a Waters Symmetry C18 high-performance liquid chromatography column. The aqueous and organic mobile phases were 2 mmole/L of ammonium acetate containing 0.1% (vol/vol) formic acid, in water and methanol, respectively. Analytes were detected using tandem mass spectrometry (Waters Acquity TQD).
RESULTS: Analytes were eluted at around 2 minutes within a 6-minute analytical run time. Detector response was linear for both analytes across the ranges studied (1-49 μg/L for sirolimus, 1-41 μg/L for everolimus), and a lower limit of quantitation of 1 μg/L was reliably attained. Intraassay and interassay imprecision and inaccuracy were <15% (coefficient of variation) in all cases. Analyte recovery was in the range of 72%-117%. The analytes were stable in blood after freezing and thawing, and for at least 12 hours after preparation while waiting to be injected. Ion suppression and interference from phospholipids were not significant.
CONCLUSIONS: A straightforward, robust liquid chromatography tandem mass spectrometry assay has been developed and validated for the simultaneous measurement of everolimus and sirolimus in small volumes of whole blood.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24305629     DOI: 10.1097/FTD.0000000000000006

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  3 in total

1.  Accuracy evaluation of automated electrochemiluminescence immunoassay for everolimus and sirolimus compared to liquid chromatography-tandem mass spectrometry.

Authors:  Eun Jin Lee; Hyun-Ki Kim; Sunyoung Ahn; Woochang Lee; Hyun Soo Kim; Sail Chun; Won-Ki Min
Journal:  J Clin Lab Anal       Date:  2019-06-14       Impact factor: 2.352

2.  Development and Validation of a Bioanalytical LC-MS/MS Method for Simultaneous Determination of Sirolimus in Porcine Whole Blood and Lung Tissue and Pharmacokinetic Application with Coronary Stents.

Authors:  Thi-Thao-Linh Nguyen; Van-An Duong; Dang-Khoa Vo; Jeongae Jo; Han-Joo Maeng
Journal:  Molecules       Date:  2021-01-15       Impact factor: 4.411

3.  Comparison of LC-MS/MS and EMIT methods for the precise determination of blood sirolimus in children with vascular anomalies.

Authors:  Yue-Tao Zhao; Hao-Ran Dai; Yue Li; Yuan-Yuan Zhang; Hong-Li Guo; Xuan-Sheng Ding; Ya-Hui Hu; Feng Chen
Journal:  Front Pharmacol       Date:  2022-09-06       Impact factor: 5.988

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.